MAP2K1 and B-cell chronic lymphocytic leukemia: Among the CLL patients who did not respond to Idelalisib therapy, 60% of the nonresponders have been identified with activating MAP2K1, BRAF, and KRAS mutations based on the whole-exome sequencing data.